Seeking Alpha

The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from...

The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals (ALNY), with Medicines paying $25M up front, as much as $180M in milestones, and then royalties. The treatment inhibits a protein called PCSK9 and is seen as an alternative to statins such as Lipitor. However, ALN-PCS is only in Phase I trials.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|